Literature DB >> 22449949

The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation.

Carole Le Henaff1, Annelise Gimenez, Eric Haÿ, Caroline Marty, Pierre Marie, Jacky Jacquot.   

Abstract

The F508del mutation in the cystic fibrosis transmembrane conductance regulator (Cftr) gene is believed to be an independent risk factor for cystic fibrosis-related bone disease. In this study, we evaluated the bone mineral density as well as the histomorphometric parameters of bone formation and bone mass in both F508del-Cftr homozygous mice (F508del Cftr(tm1Eur)) and Cftr(+/+) littermate controls at 6 (prepubertal), 10 (pubertal), and 14 (young adult) weeks of age in both sexes. The bone architecture of F508del Cftr(tm1Eur) and wild-type (WT) littermate mice was evaluated by bone densitometry, microcomputed tomography, and analysis of the dynamic parameters of bone formation. Serum levels of both insulin-like growth factor 1 and osteocalcin also were determined. Reduced bone mineral density, lower femoral bone mass, and altered trabecular bone architecture were observed in F508del Cftr(tm1Eur) mice compared with controls at 6, 10, and 14 weeks of age. A decrease in the bone formation rate in F508del Cftr(tm1Eur) mice was shown compared with control mice, independently of age and sex. In addition, we found lower insulin-like growth factor 1 levels in F508del Cftr(tm1Eur) mice compared with age-matched controls, whereas osteocalcin levels were normal. Severe osteopenia and altered bone architecture were found in young and mature adult F508del Cftr(tm1Eur) mice. Our findings show that the F508del mutation in CFTR impacts trabecular bone mass by reducing bone formation.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449949     DOI: 10.1016/j.ajpath.2012.01.039

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  Absence of leptin signaling allows fat accretion in cystic fibrosis mice.

Authors:  Ilya R Bederman; Gavriella Pora; Maureen O'Reilly; James Poleman; Kimberly Spoonhower; Michelle Puchowicz; Aura Perez; Bernadette O Erokwu; Alex Rodriguez-Palacios; Chris A Flask; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-08-17       Impact factor: 4.052

2.  Anoctamin-6 controls bone mineralization by activating the calcium transporter NCX1.

Authors:  Jiraporn Ousingsawat; Podchanart Wanitchakool; Rainer Schreiber; Manuela Wuelling; Andrea Vortkamp; Karl Kunzelmann
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

Review 3.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

4.  Increased NF-κB Activity and Decreased Wnt/β-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice.

Authors:  Carole Le Henaff; Rafik Mansouri; Dominique Modrowski; Mylène Zarka; Valérie Geoffroy; Caroline Marty; Nadine Tarantino; Emmanuel Laplantine; Pierre J Marie
Journal:  J Biol Chem       Date:  2015-06-09       Impact factor: 5.157

5.  Children and adolescents with cystic fibrosis display moderate bone microarchitecture abnormalities: data from high-resolution peripheral quantitative computed tomography.

Authors:  C Braun; J Bacchetta; P Braillon; R Chapurlat; J Drai; P Reix
Journal:  Osteoporos Int       Date:  2017-08-09       Impact factor: 4.507

Review 6.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

7.  Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis.

Authors:  M S Putman; L B Greenblatt; L Sicilian; A Uluer; A Lapey; G Sawicki; C M Gordon; M L Bouxsein; J S Finkelstein
Journal:  Osteoporos Int       Date:  2016-03-07       Impact factor: 4.507

Review 8.  Cystic fibrosis-related bone disease: insights into a growing problem.

Authors:  Michael S Stalvey; Gregory A Clines
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-12       Impact factor: 3.243

Review 9.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

Review 10.  Bisphosphonates for osteoporosis in people with cystic fibrosis.

Authors:  Louise S Conwell; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2014-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.